Ignite Creation Date:
2024-05-06 @ 1:24 PM
Last Modification Date:
2024-10-26 @ 1:13 PM
Study NCT ID:
NCT04012229
Status:
COMPLETED
Last Update Posted:
2019-07-09
First Post:
2019-04-29
Brief Title:
IMpact of Breast cAncer Gene Status on Survival in Adjuvant Breast Cancer IMBASSA
Sponsor:
Centre Hospitalier Universitaire de Besancon
Organization:
Centre Hospitalier Universitaire de Besancon
Study Overview
Official Title:
IMpact of BrcA Status on Survival in Adjuvant Breast Cancer IMBASSA
Status:
COMPLETED
Status Verified Date:
2019-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
IMBASSA
Brief Summary:
Relationship between the presence of the BRCA mutation BReast Cancer and outcomes is unclear in high-risk early breast cancers BC
This study is a multi-center retrospective cohort of patients treated in region Franche-Comté for an early BC by neoadjuvant andor adjuvant chemotherapy
The primary aim was to describe clinical and pathological characteristics considering BRCA mutated BRCAm patients versus BRCA wild type BRCAwt patients or untested patients The second objective was to assess the prognostic impact of germinal BRCAm in this high-risk population
This study is a multi-center retrospective cohort of patients treated in region Franche-Comté for an early BC by neoadjuvant andor adjuvant chemotherapy
The primary aim was to describe clinical and pathological characteristics considering BRCA mutated BRCAm patients versus BRCA wild type BRCAwt patients or untested patients The second objective was to assess the prognostic impact of germinal BRCAm in this high-risk population
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None